SG Americas Securities LLC Reduces Position in IDEXX Laboratories, Inc. $IDXX

SG Americas Securities LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,425 shares of the company’s stock after selling 1,608 shares during the quarter. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $29,378,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Empowered Funds LLC grew its position in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IDEXX Laboratories during the second quarter worth $265,000. Global Retirement Partners LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $238,000. Insigneo Advisory Services LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $296,000. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of IDEXX Laboratories by 43.2% in the second quarter. Steward Partners Investment Advisory LLC now owns 3,860 shares of the company’s stock worth $2,070,000 after purchasing an additional 1,165 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $573.29 on Friday. The firm has a 50 day moving average of $634.46 and a 200 day moving average of $662.53. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $45.59 billion, a price-to-earnings ratio of 43.86, a price-to-earnings-growth ratio of 3.50 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm earned $2.53 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $783.33.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,957 shares of company stock valued at $29,862,109 over the last 90 days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.